Competitor Analysis: SARS-CoV-2 Treatment & Prevention Approaches
This Competitive Intelligence report about SARS-CoV-2 Treatment & Prevention Approaches describes the landscape of industry-driven approaches to evaluate existing, discover novel treatments and vaccines for COVID-19.
COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Industry alone or collaboration with govermnent agencies or non-governmental organizations (NGOs) have started to searh for safe and effective treatments and vaccines to fight the novel 2019 coronavirus (2019-nCoV or SARS-CoV-2) causing COVID-19 disease.
This report includes a compilation of industry-driven projects in research and development of treatments and vaccines for COVID-19. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.